200 related articles for article (PubMed ID: 22579006)
1. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
[TBL] [Abstract][Full Text] [Related]
2. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.
Lave T; Levet-Trafit B; Schmitt-Hoffmann AH; Morgenroth B; Richter W; Chou RC
J Pharm Sci; 1995 Nov; 84(11):1285-90. PubMed ID: 8587044
[TBL] [Abstract][Full Text] [Related]
3. Applicability of the Øie-Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase.
Yahata M; Ishii Y; Nakagawa T; Watanabe T; Miyawaki I
Biopharm Drug Dispos; 2020 Apr; 41(4-5):151-165. PubMed ID: 32187715
[TBL] [Abstract][Full Text] [Related]
4. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling.
Sanwald-Ducray P; Dow J
Xenobiotica; 1997 Feb; 27(2):189-201. PubMed ID: 9058532
[TBL] [Abstract][Full Text] [Related]
6. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
8. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
[TBL] [Abstract][Full Text] [Related]
11. Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.
Mahmood I
J Pharm Pharmacol; 1998 May; 50(5):493-9. PubMed ID: 9643442
[TBL] [Abstract][Full Text] [Related]
12. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
[TBL] [Abstract][Full Text] [Related]
13. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
14. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
16. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
Sayama H; Komura H; Kogayu M
Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
19. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.
Lave T; Saner A; Coassolo P; Brandt R; Schmitt-Hoffmann AH; Chou RC
J Pharm Pharmacol; 1996 Jun; 48(6):573-7. PubMed ID: 8832489
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
